329. Role of infection in exacerbations of COPD

P3008
Human metapneumovirus involved in acute exacerbations in COPD patients?

Marijke Vanapaumen1, Frits Franssen2, Catharina Bruggeman3, Emiel Wouters3,4, Catharina Linssen1, Marijke Vanspauwen1, Frits Franssen 2, Cathrien Bruggeman1, Emiel Wouters2,3,4, Rogier van der Zanden1, Paul van der Valk2, Ron Hendrix3, Job van der Palen2,4, Kris Movig2, Marjolein Bruisse-Keizer2.

1Medical Microbiology, Maastricht University Medical Centre, Maastricht, Netherlands; 2Pulmonary Medicine, Medisch Spectrum Twente, Enschede, Netherlands; 3Microbiology, Regional Laboratory of Public Health, Enschede, Netherlands; 4Research Methodology, Measurement, and Data Analysis, University of Twente, Enschede, Netherlands; 5Clinical Pharmacy, Medisch Spectrum Twente, Enschede, Netherlands

Introduction: COPD exacerbations are often treated with antibiotics, although their use is controversial. A previous study showed that patients with a sputum concentration of amoxicillin (a beta-lactam antibiotic) lower than the minimum inhibitory concentration (MIC90, value 2 mg/l) were hospitalized 4 days longer than patients with a concentration $\geq$MIC90. One explanation for a low amoxicillin concentration could be that patients' lungs are colonized or infected with pathogens that have beta-lactamase activity.

Objective: This study investigated if beta-lactamase activity was higher in patients who had a sputum amoxicillin concentration <2 mg/l than in patients with a concentration $\geq$2 mg/l.

Methods: 23 Hospitalized COPD patients treated with amoxicillin/clavulanic acid for an acute exacerbation were included. Sputum and serum samples were collected at the third day of treatment to determine beta-lactamase activity in sputum and amoxicillin concentrations in both sputum and serum.

Results: We found no difference in beta-lactamase activity between patients with a sputum amoxicillin concentration <MIC90 and $\geq$MIC90 (p=0.79). Amoxicillin concentrations were <MIC90 in 18 out of 23 sputum samples (78%). Serum concentrations amoxicillin were <MIC90 in 7 patients (30%).

Conclusions: Beta-lactamase activity did not differ between patients with sputum amoxicillin concentrations <MIC90 or $\geq$MIC90. The finding that a majority of patients had a sputum amoxicillin concentration <MIC90 is troubling. This suggests that these patients are being undertreated. Further research could focus on inhalation of amoxicillin to obtain higher concentrations in sputum.

P3009
Aromoxillin concentrations in sputum in relation to beta lactamactivity in COPD patients

Rogier van der Zanden1, Paul van der Valk2, Ron Hendrix3, Job van der Palen2,4, Kris Movig2, Marjolein Bruisse-Keizer2.

1Medical Microbiology, Maastricht University Medical Centre, Maastricht, Netherlands; 2Pulmonary Medicine, Medisch Spectrum Twente, Enschede, Netherlands; 3Microbiology, Regional Laboratory of Public Health, Enschede, Netherlands; 4Research Methodology, Measurement, and Data Analysis, University of Twente, Enschede, Netherlands; 5Clinical Pharmacy, Medisch Spectrum Twente, Enschede, Netherlands

Introduction: COPD exacerbations are characterized by an increase in symptoms of COPD over a period of time. They are often caused by infections. Human metapneumovirus (hMPV) is one of the most isolated viruses in samples collected during the stable state. Patients with hMPV in the stable state experienced more exacerbations compared to patients without any virus in the stable state.

Conclusions: hMPV was one of the most isolated viruses in samples collected during the stable state. Patients with hMPV in the stable state experienced more exacerbations compared to patients without any virus in the stable state.

P3010
Clinical and economical impact of exacerbations of chronic obstructive pulmonary disease (COPD): A two-year study

Francesco Blasi1, Carla Formari2, Francesca Di Stasi3, Sara Conti2, Lorenzo Giovanni Mantovani4,5, Luca Merlin6, Stefano Alberti7, Giancarlo Cesana8.

1Dipartimento Toraco-Polmonare e Cardio-Circolatorio, University of Milan, Italy; 2Dipartimento di Medicina Clinica e Prevenzione, University of Milano-Bicocca, Monza, Italy; 3Nycomed, Nycomed Spa, Milan, Italy; 4CRFF/Center of Pharmacoeconomics, Federico II. University of Naples, Naples, Italy; 5Regional Health Authority of Lombardy, Italy, Milan, Italy

COPD is a common disease with considerable health and economic consequences. The aim of our study was to analyze clinical and economical impact of COPD exacerbations (E-COPD). A secondary data analysis of healthcare administrative databases of Lombardy, Italy was performed, including patients hospitalized for a severe E-COPD (index event) from Jan to Dec 2003. Two study groups were identified based on the number and type of E-COPD experienced after the index event during a two-year follow-up: those who had at least one severe E-COPD (Group A) and those who had only moderate E-COPD (Group B). A total of 12,436 patients (7,933 males; mean age: 74±10 yrs) were enrolled. Among those, 45% belonged to Group A and 55% to Group B. Clinical outcomes, costs and consumptions of pulmonary function test (PFT) per person during the follow-up are given in Table.

<table>
<thead>
<tr>
<th>Group</th>
<th>Deaths, n (%) ptxa</th>
<th>E-COPD, mean (SD)a</th>
<th>Hospitalization cost, mean (SD)a</th>
<th>Prescription cost, mean (SD)a</th>
<th>Patients with PFTs, n (%)</th>
<th>PFTs cost, mean (SD)a</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group A</td>
<td>1,503 (27)</td>
<td>6.3 (4.98)</td>
<td>9,609 (9,399-9,929)</td>
<td>1,542 (1,512-1,582)</td>
<td>1,350 (24)</td>
<td>1,345 (22)</td>
</tr>
<tr>
<td>Group B</td>
<td>1,502 (22)</td>
<td>3.9 (3.85)</td>
<td>4,647 (4,526-4,779)</td>
<td>1,195 (1,168-1,229)</td>
<td>1,354 (22)</td>
<td>12 (12-13)</td>
</tr>
</tbody>
</table>

Cost in EUROS. *p<0.01 Age-adjusted difference between groups.

Mortality risk increased in the study population in relation to the number and type of E-COPD experienced during the follow-up. The number and type of
Introduction: Patients with COPD are chronically colonized with bacteria and can benefit from long-term antibiotic therapy. Ciprofloxacin dry powder for inhalation (DPI) is an investigational PulmoSphere™ formulation for pulmonary delivery of ciprofloxacin.

Aim: To investigate the safety, tolerability and PK of ciprofloxacin DPI in patients with COPD.

Methods: In a randomized, phase I, single-blind, parallel-group study, adults with GOLD stage II or III COPD received 32.5 mg or 48.75 mg ciprofloxacin (50 mg, 75 mg ciprofloxacin DPI, respectively) or matching placebo as a single dose on Day 0 and Day 12 on bid on Days 2-11.

Results: Patients received 32.5 mg (n=6) or 48.75 mg (n=9 including 3 who replaced drop-outs) ciprofloxacin, or placebo (n=6). There were no severe or serious AEs; most AEs were mild in severity. There were treatment-related AEs in 4, 8 and 1 patients in the 32.5 mg and 48.75 mg ciprofloxacin and placebo groups, respectively. Three patients discontinued (48.75 mg ciprofloxacin) due to AEs. No clinically significant laboratory test results were not fully understood. Day 0 geometric mean plasma ciprofloxacin AUC 0.532 mg·h/μl and 0.727 mg·h/μl, and AUC@inf in induced sputum was 1.90 mg·h/μl and 2.010 mg·h/μl, for the 32.5 mg and 48.75 mg groups, respectively. Ciprofloxacin sputum concentrations were highly variable with geometric mean induced sputum Cmax plasma Cmax ratios ranged 1650–10,600.

Conclusions: Ciprofloxacin DPI was well tolerated over 12 days’ treatment in patients with moderate or severe COPD. High sputum concentrations contrasted with low systemic exposure.

Introduction: Respiratory viruses are associated with acute exacerbations (AE) in patients with COPD, but may also lead to asymptomatic carriage. This study investigates whether co-detection of viruses in the stable state predisposes for AEs in patients with COPD. Since it is known that many viruses circulate during the year, we aimed to identify the most important respiratory viruses in the stable state of COPD patients.

Material and methods: From March 2009 until August 2010 sputum samples of COPD patients clinically rehabilitating at the centre of expertise for chronic obstructive pulmonary disease were included. Sputum samples were collected during the stable state and during an AE. Real-time polymerase chain reaction for rhinovirus, hMPV, RSV, influenza A and B and parainfluenza 1-4, was performed.

Results: A total of 406 sputum samples (218 patients) were included. Viruses were detected in 208 samples (42%) of which 106 (51%) were collected during the stable state. In 11% of the samples multiple viruses were found, of which the combination of rhinovirus and hMPV was the most frequent (58%). Patients with multiple viruses in the stable sample did not experience more AEs in the first weeks after stable sample collection than patients with a single virus or without a virus in the stable sample.

Conclusion: In 11% of sputum samples of COPD patients multiple respiratory viruses were found. The presence of multiple viruses does not predispose these patients to the short-term occurrence of an AE.

Method: PBMCs were stimulated for 24h, with 10μM R848 and 1μM CpG, from healthy controls & COPD subjects. IFN-α release was measured in supernatant using ELISA kits.

Results: 37 COPD & 8 healthy control subjects were recruited. The mean (SD) FEV1 (%) (L) & FEV1/FVC of the COPD subjects was 1.32 (0.58) & 0.5 (0.13) respectively. There was no significant difference in IFN-α (pg/ml) release when comparing health 74 (30) to COPD 59 (42) (p=0.33) when stimulating TLR 7. TLR 9 stimulation gave a significant increase in IFN-α production in COPD 204 (106) vs health 114 (61) (p=0.003). TLR 9 stimulation was significantly increased compared to TLR7 in COPD (p=0.017). There was a significant negative correlation with lung function and TLR7 stimulation in the COPD group, FEV1 (% disposable, p=0.046, p=0.005). FEV1/FVC % predicted (r=0.37, p=0.024); FEV1/FVC (r=0.39, p=0.002). TLR 9 stimulation had a significant negative correlation with age exchange, KCO% predicted (r=0.53, p<0.001) and TLC% predicted (r=0.43, p=0.01).

Conclusion: The release of IFN-α by PBMCs was increased in COPD compared to healthy controls following TLR 9, but not TLR 7 stimulation. The IFN-α release after TLR7 & 9 activation was related to lung function.
P3016 Exacerbation frequency is related to PEF self-similarity in COPD

Gavin Donaldson1, Terence Seemungal2, John Hurst1, Jadhija Wedzicha1.
1Academic Unit of Respiratory Medicine, University College London Medical School, London, United Kingdom; 2Department of Clinical Medical Sciences, University of the West Indies, St. Augustine, Trinidad and Tobago

Introduction: Self-similarity in Peak Expiratory Flow (PEF) can predict the frequency of asthmatic events but it is unknown whether in COPD there is a relationship with exacerbation frequency.

Methods: We examined data from the London COPD cohort on 308 COPD patients who recorded worsening of respiratory symptoms and PEF on daily diary cards. Exacerbations were identified as previously described (Seemungal. AJRCCM 157:1418-1422, 1998) from which an annual rate was calculated. Detrended fluctuation analysis was used to calculate α which is a measure of decay in self-correlation over time (Frey et al Nature. 438: 667-70, 2005). PEF time series when the patient was clinically stable were also analyzed by excluding data collected 1 day before to 7 day after each exacerbation, and splicing the series together.

Results: The 308 COPD patients (155M; mean age (SD) 68.3 (8.4) years; FEV1 1.1 (0.8) l, PEF predicted 45.5 (16.4); PEFi predicted 54.7 (18.6). The cohort recorded diary card data for a median 1077 days and experienced 2621 exacerbations with a median frequency of 2.04 per year (IQR 0.9 - 3.3). The patients had an α of 0.944 (SD 0.19) over the initial 365 days which was positively related to exacerbation frequency (negative binomial regression, P=0.009). No difference was seen if exacerbation PEF data were excluded, α = 0.935 (SD 0.21; P=0.139) and there was also a relationship with exacerbation frequency (P=0.001).

Conclusion: In COPD patients, long-term correlations (self-similarity) exist in PEF, which are related to exacerbation frequency. The exponent α may prove a useful marker of exacerbation frequency and as normally distributed lead to a reduction in the number of patients required for clinical trials.

P3017 The role of respiratory virus infection in COPD exacerbations

Xavier Pomares1, Silvia Capilla2, Concepción Montón1, Dolores Mariscal1, M.A. Marcos1, Mateu Espasa1, Eduard Moló1, Miquel Gallegos2.
1Pneumology, Corporació Sanitària Parc Taulí, Sabadell, Barcelona, Spain; 2Microbiology, Corporació Sanitària Parc Taulí, Sabadell, Barcelona, Spain; 3Microbiology, Hospital Clinic, Barcelona, Spain

Aim: To determine the prevalence of viral infection in a cohort of severe COPD patients.

Methods: We conducted a prospective observational study in a cohort of severe COPD patients from 2005 to 2007. We recorded for each exacerbation: etiological agent, prior antibiotic prescription, corticosteroid treatment and days of hospitalization. Sputum samples were collected and the Gram staining Murray-Washington’s grade was done. A multiplex retrotranscriptase-nested PCR assay was used for simultaneous detection of Parainfluenza virus (1, 2, 3, 4AB), human Coronavirus 229E and OC43, Enterovirus, Rhinovirus, Influenza virus A, B, C, Respiratory syncytial virus and Adenovirus following the procedure described by Cottas et al. (J Med Virol 72:484-95).

Results: A total of 118 patients were registered with a mean age of 69.8±8.0 years. 60% were in GOLD stage IV. Among the 307 respiratory samples processed 89% (275/313) were Murray grade IV and 66.1% (203/307) of them had positive respiratory bacterial pathogens (positive cultures). Overall, virus were detected in 110/307 (35.8%) of analyzed samples, being Rhinovirus the most common of them (22%). In 51% (377/727) of bacterial negative culture samples virus were detected, while in 31% (63/203) of bacterial positive cultures virus co-infection was observed (p<0.05).

Conclusions:
- The prevalence of virus infection in our cohort was 36%, being Rhinovirus the most common virus.
- A respiratory viral infection may be suspected in COPD exacerbations among patients with negative bacterial culture.

Granted by Fundació Marató TV3

P3018 Presence of Pneumocystis jiroveci colonization in patients with COPD

Marijke Vanspaepoen1, Frits Franssen2, Cathrien Bruggeman1, Emiel Wouters2,3.
1Academic Unit of Respiratory Medicine, University College London Medical School, London, United Kingdom; 2Ciro+, Centre of Expertise for Chronic Organ Failure, Horn, Netherlands; 3Respiratory Medicine, Maastricht University Medical Centre, Maastricht, Netherlands

Introduction: Pneumocystis jiroveci infections are frequently detected in immuno-compromised patients. However, evidence suggests that P. jiroveci can be detected in non-immuno-compromised patients, where it colonizes the airways. Over the past years, P. jiroveci has been linked with COPD. P. jiroveci colonization may be associated with the severity of COPD and some evidence suggests a role for P. jiroveci in the progression of COPD in smokers. The present study investigates the presence of P. jiroveci in sputum samples of patients with COPD.

Material and methods: From March 2009 until September 2010, sputum samples from COPD patients clinically rehabilitating at the centre of expertise for chronic organ failure (CIRO) were included. Patients were followed during an 8 week period and sputum samples were collected during the stable state and during an acute exacerbation (AE). Sputum samples were analyzed for the presence of P. jiroveci by a real-time PCR assay.

Results: During the study period 509 sputum samples (218 patients) were collected clinically rehabilitating at CIRO Horn. A total of 184 samples (36%) were collected during the stable phase and 325 (63.8%) during an AE. P. jiroveci DNA was detected in 40 (8%) of all sputum samples. A total of 23 positive samples (57.5%) were detected during an AE and 17 during the stable state (42.5%).

Conclusion: In our population, P. jiroveci colonization could be detected in 8% of the sputum samples of COPD patients. Additional research is needed to clarify the role of P. jiroveci in the pathophysiology of COPD.

P3019 Microbiological efficacy of combined use of vaccines against S. pneumoniae, H. influenzae type B in patients with COPD

Andrey Protasov1, Alexandr Zhestkov1, Mihail Kostinov2, Alexey Ryzhov2.
1Department of General and Clinical Microbiology, Immunology and Allergology, Samara State Medical University, Samara, Russian Federation; 2Laboratory of Vaccination and Immunotherapy of Allergic Diseases, Ilia Illich Mechnikov – Research Institute of Vaccines and Serum, Moscow, Russian Federation

Purpose: To determine the influence of the compatible vaccination “Pneumo-23”, “Hiberix” on microbial flora of sputum in patients 12 months after the vaccination.

Materials and methods: The microbiological sputum examination of 31 patients vaccinated with “Pneumo-23”, “Hiberix” was made before and 12 months after the vaccination. Pneumococcal bacteria were identified by the sensitivity to optochin, lysis in the presence of bile salts. To isolate H. influenzae paper disks with bacitracin were used. M. catarrhalis was identified by using commercial sets (Gonochek-II), Staphylococcus spp. was revealed by the microscopic method.

Results: In 26 of the 31 patients M. catarrhalis was isolated from the sputum before the vaccination. S. pneumoniae was found in 80.6±5.1% of the cases. In 3 patients K. pneumoniae was isolated, H. influenzae – in 12.9±6.0% of the patients. In 3 patients A. baumannii was isolated, S. spp. – in 6.4±4.4% of the patients, M. orotatus was found in 1 patient.

1 month after the vaccination in 3 patients 6.9±5.3% of the cases, a P value = 0.001). S. pneumoniae was isolated. The statistical significant differences in the number of the patients with H. influenzae, M. catarrhalis, S. spp., K. pneumoniae, M. orotatus, A. baumannii sputum were not detected 12 months after the vaccination.

Conclusion: The compatible vaccination significantly reduces the occurrence of S. pneumoniae in the sputum of COPD patients, prevents sputum from the colonization by H. influenzae and S. pneumoniae, may be recommended for a prophylactic and therapeutic purposes.

P3020 Etiology pathogens structure in community-acquired pneumonias and COPD exacerbations

Alina Martynova, Ekaterina Nosuch, Alexander Sheryarov. Epidemiology Department, State Medical University, Vladivostok, Russian Federation

Purpose: To determine the influence of the compatible vaccination “Pneumo-23”, “Hiberix” on microbial flora of sputum in patients 12 months after the vaccination.

Materials and methods: We examined 200 adults with CAP and 200 adults with COPD exacerbations of the same age (20-45 years), isolated strains of S-pneumoniae and H.influenzae were checked for antimicrobial agents resistance according to NCCLS standards, typed and studied by MLST.

Results: In 1st group S. pneumoniae was isolated in 42%, H. influenzae in 26%. In the 2nd group pneumococci were isolated in 36%. Antimicrobial resistance (1st group vs 2nd group) of S. pneumoniae were characterized with resistance to erythromycin (14%/18%), levofloxacin (9%/7%). H. influenzae strains were resistant to co-trimoxazole (20%/27%) and ampicillin (24%/28%). Serotyping of S. pneumoniae revealed that the most of the 2nd group strains were of the serotypes including to the 23-polyvalvar vaccine. H. influenzae strains of the L, II, and III were the prevalent bactenotypes. MLST of S. pneumoniae showed the prevalence of several lineage clones in CAP strains (1st group).

Conclusion: The microbiological monitoring of the main respiratory pathogens could be significant instrument both in clinical diagnostics and in epidemiology surveillance of the lower respiratory tract infections.
COPD exacerbation
Bronchial brush-biopsies cells in dependence on infectional agent species at high at infectional COPD exacerbation.

Polyvalent mechanical bacterial lysate

Proinflammatory cytokines (Il-8, TNF-α) levels in sputum and blood were high than in second group: TNF-α level was high in H.influenzae, Ch.pneumoniae, M.pneumoniae 14.6 ± 2.5%, 15.1 ± 2.5% respectively, in M.catarrhalis agents (5.3 ± 1.1%, 8.4 ±4.1.5%, 8.9 ± 1.9%, 5.1 ±2.3%). Squamous metaplased cells was high (p < 0.05) in H.influenzae, Ch.pneumoniae, M.pneumoniae (6.3 ± 1.2%, 7.5 ±1.2%, 7.4 ±1.6%) than in S.pneumoniae, M.catarrhalis agents (2.5 ±0.6%, 2.2 ±0.7%). Dysrophic epithelial cells count was high (p <0.05) in H.influenzae, Ch.pneumoniae (56.6±2.2%, 54.9±2.8%) than in Ch.pneumoniae, M.pneumoniae M.catarrhalis agents (46.9±3.0%, 44.7±3.5%, 38.9±4.4%). Neutrophils count was high (p < 0.05) in H.influenzae, Ch.pneumoniae (50.2±6.4%, 56.5±4.2%) than at S.pneumoniae, M.pneumoniae M.catarrhalis agents (36.0±4.0%, 38.0±4.6%, 34.8±4.6%).

H.influenzae, Ch.pneumoniae have more infected effects, but M.pneumoniae result in high growth activity.

P3023 Modification of cell mediated immune-response in patients treated with a polyvalent mechanical bacterial lysate
Fulvio Braido1, Elisabetta Traggiai 2, Giulia Lanzilli, Gjada Bazorrø, Chiara Follì, Valentina Garelli, Anna Maria Raccu 1, Giovanni Melillo 1.
1Clinica Malattie dell’Apparato Respiratorio e Alergo, AOU San Martino, Genova, Italy; 2Laboratorio di Immunopatologia e Reumatologia, Istituto G. Gaslini, Genova, Italy; 3Laboratorio di Immunologia, CNR, Roma, Italy; 4Laboratorio Centrale di Analisi, Istituto G. Gaslini, Genova, Italy

Background: Efficacy of Polyvalent Mechanical Bacterial Lysate (PMBL) in inducing the secretion of specific IgA directed to the bacterial antigens administered has been shown.

Aims and objectives: In this double blind placebo controlled study, we analyzed the immunological effect of PMBL, administered to a population of elderly Chronic Obstructive Pulmonary Disease (COPD) patients.

Methods: The treatment provided 1 tablet of PMBL for the first ten days of the month, followed by a 20 day rest. The treatment was repeated for other two months and the follow up was carried out up to six months. Blood cell samples were collected at time 0 (before the beginning of the study), after three months and after six months.

Results: CD4+ and activated T cells increased significantly in treated group, while Treg were significantly reduced. Transitional B cells (in particular T3) were recruited and associated to an increase of early naive B cells; recruitment of early memory cells was associated to a reduction of "classic" memory B cells. Finally, NK cells were significantly increased in treated patients, while their subpopulations remained unaltered.

Conclusion: In conclusion, PMBL administration causes in COPD patients an important recruitment of cells belonging to the innate immune system, such as NK, a significant activation of early B cell compartments and a clear reduction of regulatory T cells associated to the increase of T cell activation. All these findings confirm that, also in COPD patients, a specific (and also partially polyclonal) activation of B cells occur, and this seems to be strictly related to the significant clinical results observed.

P3024 Role of endothelial dysfunction, disturbance of haemostatic reactions in pathogenesis of acute exacerbation of chronic obstructive pulmonary disease (AE COPD)
1Department of Therapy and Family Medicine of Faculty of Postdiplom Education, Altai State Medical University, Barnaul, Russian Federation; 2Altai Hemathological Scientific Centre, Barnaul, Russian Federation; 3Department of Laboratory Diagnostic, Altai Regional Clinical Hospital, Barnaul, Russian Federation; 4Department of Pulmonology, Municipal Hospital No. 5 of Barnaul, Barnaul, Russian Federation; 5Department of Pulmonology, Institute of Pulmonology of Federal Medico-Biological Agency of Russian Federation, Moscow, Russian Federation

Purpose: It is to research interrelations of endothelial dysfunction, system inflammatory and haemostatic reactions at patients with AE COPD.

Materials and methods: In open prospective clinical investigation 111 patients with 2 or 3 positive criteria Anthonissen et al. (1987) were included. Men were 91 people (82%), women - 20 people (18%). The smoking index was 37.5±2.06 pack-years. Patients with AE COPD divided on two subgroups: 1st - patients without bronchoctasia, 2nd - patients with bronchoctasia. All patients received therapy system glucocorticoids. The control group included 35 healthy non-smoking people with middle age 25.9±1.36 years, from them 27 (77,1%) men and 8 (22.9%) women. It was accomplished immunenyme definition of CRP, endotelin-1, D-dimers and homocystein maintenance in blood before treatment.

Results: Direct correlation communication between indexes CRP and endotelin-1 (r=0,80, p<0.01), indexes CRP and D-dimers (r=0,65, p<0.01) in the AE COPD group were observed. Dynamics of indexes of endothelial dysfunction and thrombogenic risk at patients with various phenotypes AE COPD are in table 1.

Table 1

<table>
<thead>
<tr>
<th>Indicators</th>
<th>Control group</th>
<th>Patients subgroup 1</th>
<th>Patients subgroup 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRP (mg/l)</td>
<td>3.30±0.14</td>
<td>6.51±1.97</td>
<td>13.33±3.24*</td>
</tr>
<tr>
<td>ETA-1 (f/ml)</td>
<td>0.30±0.04</td>
<td>1.80±0.55*</td>
<td>1.20±0.38*</td>
</tr>
<tr>
<td>D-dimer (mg/l)</td>
<td>0.10±0.02</td>
<td>0.60±0.12*</td>
<td>1.60±0.45*</td>
</tr>
</tbody>
</table>

*p Patients subgroup vs. control p<0.05

Conclusion: At patients with AE COPD it is increased levels of D-dimers, which indicates that specifies on thrombogenic and thromboembolic risks.

P3025 Invasive pulmonary aspergillosis in patients with severe COPD. Comparative study between probable invasive infection and colonization
Rosana Blavía1, Antonia Flox2, Isabel Serret2, Montserrat Moll3, Dolores Estivill3, Ramon Trullas4, Damian Perich1, Esperanza Martin1, Conxa Perez1, Emilio Marquilles1.
1Pulmonology, Manresa Hospital - Abtaia, Manresa, Barcelona, Spain; 2Internal Medicine, Manresa Hospital - Althaus, Manresa, Barcelona, Spain; 3Microbiology, Manresa Hospital - Althaus, Manresa, Barcelona, Spain; 4Radiology, Manresa Hospital - Althaus, Manresa, Barcelona, Spain

This retrospective study included patients with chronic respiratory disease with aspergillosis isolation in respiratory cultures from Jan-07 to Dec-09. The diagnosis of probable invasive pulmonary aspergillosis (IPA) was based on comparable clinical setting and IRCT findings. A univariate comparative analysis between IPA probable and aspergillosar colonization was carried out.

Results: Of the 103 patients recruited 66 patients were excluded. Of the remaining 37 we diagnosed 15 patients (14%) with IPA probable and 22 (21%) as colonization. COPD in 73% of patients (80% GOLD III-IV). The prior use of corticosteroids was higher in IPA, with a greater accumulate mean 405 mg in IPA 74 mg in colonized (p<0.05). A greater number of hospital admissions were detected in IPA. The mean length of hospital stay was higher in IPA with 35±28 days.
days as opposed to 13±22 d. in colonization (p:0.003) and respiratory failure (80% IPA v 36% p:0.009). Antifungal therapy was received by 91% of IPA and by 36% of colonized. The overall mortality rate was 47% in IPA and 23% in colonization.

Conclusions: 1. Immunosupression by corticosteroids in COPD patients Gold III-IV is the major risk factor for invasive aspergillosis. 2. The absence of clinical improvement in correctly treated exacerbations of severe COPD and recurrent isolation of aspergillus in sputum should point to the possibility of the existence of IPA and demand a HRCT scan. 3. HRCT findings can detect early IPA in the shape of bronchial spread once bacterial or mycobacterial infections have been ruled out.